Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder

NCT02722538 is registered in ClinicalTrials.gov with Taris Biomedical LLC as lead sponsor.

NCT NCT02722538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02722538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder
Lead sponsor
Taris Biomedical LLC
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2016
Completion date
May 2, 2019
Enrollment
23 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder cancer